- Home
- CYTK vs IONS Comparison
CYTK vs IONS Comparison
Compare CYTK & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTK
- IONS
- Stock Information
- Founded
- CYTK 1997
- IONS 1989
- Country
- CYTK United States
- IONS United States
- Employees
- CYTK N/A
- IONS N/A
- Industry
- CYTK Biotechnology: Pharmaceutical Preparations
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- CYTK Health Care
- IONS Health Care
- Exchange
- CYTK Nasdaq
- IONS Nasdaq
- Market Cap
- CYTK 5.7B
- IONS 6.0B
- IPO Year
- CYTK 2004
- IONS 1991
- Fundamental
- Price
- CYTK $45.82
- IONS $32.68
- Analyst Decision
- CYTK Buy
- IONS Buy
- Analyst Count
- CYTK 15
- IONS 18
- Target Price
- CYTK $83.64
- IONS $62.00
- AVG Volume (30 Days)
- CYTK 1.1M
- IONS 1.5M
- Earning Date
- CYTK 02-25-2025
- IONS 02-19-2025
- Dividend Yield
- CYTK N/A
- IONS N/A
- EPS Growth
- CYTK N/A
- IONS N/A
- EPS
- CYTK N/A
- IONS N/A
- Revenue
- CYTK $3,219,000.00
- IONS $803,067,000.00
- Revenue This Year
- CYTK N/A
- IONS N/A
- Revenue Next Year
- CYTK $710.83
- IONS $10.85
- P/E Ratio
- CYTK N/A
- IONS N/A
- Revenue Growth
- CYTK N/A
- IONS 30.57
- 52 Week Low
- CYTK $44.49
- IONS $31.40
- 52 Week High
- CYTK $84.92
- IONS $52.49
- Technical
- Relative Strength Index (RSI)
- CYTK 39.27
- IONS 40.58
- Support Level
- CYTK $44.49
- IONS $31.40
- Resistance Level
- CYTK $48.45
- IONS $35.37
- Average True Range (ATR)
- CYTK 1.65
- IONS 1.31
- MACD
- CYTK -0.08
- IONS -0.23
- Stochastic Oscillator
- CYTK 23.50
- IONS 29.09
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.